ROCKVILLE, MD, SEATTLE, WA (USA) June 23, 2009
-MEDIFACTS INTERNATIONAL, INC. a leading global cardiovascular core lab announced today the acquisition of the Clinical Trials Services division of Spacelabs Healthcare, Inc. (“CTS”). Financial terms of the transaction were not disclosed.
The combination of Medifacts International and CTS, a global provider of integrated, centralized cardiovascular safety and diagnostic services to the pharmaceutical and biotechnology industries, brings together Medifacts’ industry-leading scientific and regulatory expertise, global logistics and support infrastructure with CTS’ demonstrated commitment to technology, service excellence and client-focused solutions.
Michael Woehler, PhD, President and CEO of Medifacts said: “This combination brings together two highly motivated teams that share a passion for delivering the highest quality service, and creates the broadest product offering of cardiac safety and efficacy services for Phase I through IV clinical trials to pharmaceutical, biotech and medical device manufacturers worldwide. We are delighted to welcome the CTS team into the Medifacts organization today.”
Dr Woehler added, “The combination enhances our existing client relationships and creates an even stronger partner for new and existing clients alike. Medifacts is committed to assisting companies navigate the complex regulatory and scientific requirements throughout the drug development clinical trial process in a fast and cost efficient manner. Our acquisition of the CTS business today is a further demonstration of that commitment.”
John Carpentier, General Manager of CTS commented, “Through the combination with Medifacts, we will be able to provide existing and future clients with a wide array of ECG, Holter, and Blood Pressure technologies supported by the industry's most experienced technologists and scientific experts. I am excited to be joining the Medifacts group and look forward to serving all of our clients as a part of this world class team.”
About MEDIFACTS
Driven by best-in-class Science, Technology, and Service Quality, Medifacts International has become a global leader providing ECG, Holter, Ambulatory Blood Pressure Monitoring, Spirometry, Glucometry, Pulse Wave Analysis and related services to pharmaceutical, biotech and medical device companies.
Medifacts International’s scientific expertise, proprietary WebHeart® technology, global presence and recognized quality leadership has established Medifacts as one of the top 3 providers worldwide in comprehensive cardiac safety and efficacy services
About SPACELABS HEALTHCARE, INC.
Spacelabs Healthcare, Inc.
is an international developer, manufacturer and distributor of medical equipment and services including patient monitoring solutions, anesthesia delivery and ventilation systems, diagnostic cardiology solutions and supplies and accessories selling to hospitals, clinics and physicians offices. Additionally, the company provides ECG laboratory services to pharmaceutical companies undertaking clinical trials, whereby patient ECG data is recorded, analyzed, tabulated and interpreted.
The company has established brand names in both medical devices and medical services such as "Spacelabs," "Blease," Del Mar Reynolds and "Dolphin." It employs approximately 1,500 personnel in its offices located in the United States, UK, Canada, France, Germany, Finland, India and Singapore.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.